• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Small Innovators & Niche CROs

    Focus on Science

    Rapid and Data Rich Chromatographic Method Development

    Preparing Your Post Pandemic Talent Strategy

    How Modern Near-Infrared Came to Be
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Microbiologics Expands Virology Services

    ATMPS, Ori Biotech Integrate Digital Platform for Cell & Gene Therapies

    Executive Moves: Novavax

    Albumedix Completes Commercial-Scale Mfg. Facility Expansion

    Catalent Biologics Completes Madison Expansion
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Albumedix Completes Commercial-Scale Mfg. Facility Expansion

    Ensuring Pharma Manufacturing Quality

    Exploring ICP-MS expertise at Almac

    Catalent Biologics Completes Madison Expansion

    Ascendia Pharmaceuticals Poised for Expansion
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Cryoport Acquires Critical Transport Solutions Australia

    PharmParts – This Makes Sense!

    Securing Your API Supply Chain: Three Keys to Success

    Enteris BioPharma: Custom Solutions – From Bench to Market

    The Benefits of Outsourcing Cold Storage
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Microbiologics Expands Virology Services

    ATMPS, Ori Biotech Integrate Digital Platform for Cell & Gene Therapies

    Albumedix Completes Commercial-Scale Mfg. Facility Expansion

    Exploring ICP-MS expertise at Almac

    Catalent Biologics Completes Madison Expansion
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Ensuring Pharma Manufacturing Quality

    What Will Change at FDA for 2021?

    RBQM Comes of Age: COVID as a Catalyst for Change

    Post-Pandemic Regulations

    Enteris BioPharma: Custom Solutions – From Bench to Market
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Alcami

    Emergent BioSolutions

    Quotient Sciences

    Almac Group

    Adare Pharma Solutions
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Aphena Pharma Solutions

    Syngene

    Reed-Lane

    Almac Group

    Adare Pharma Solutions
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Columns

    An “All-You-Can-Eat” Buffet for Excellence

    Or, touching on almost all editorial subjects for the month

    An “All-You-Can-Eat” Buffet for Excellence
    Related CONTENT
    • Piramal Invests $32M to Expand Michigan Facility
    • Emphasizing Sustainability in Contract Manufacturing
    • Sterling Pharma Solutions Expands US Operations
    • Vetio Animal Health
    • Pfizer Signs $425m Flu Vaccine Deal with BioNTech
    Emil W. Ciurczak, DoraMaxx Consulting09.11.18
    I was pondering which of this month’s editorial “bullet points” I would discuss when an idea hit me. Why not just talk about them all? Namely, for me, Global Outsourcing Strategies, Clinical Trial Supplies, and HPAPI’s (high potency APIs) all work together. In fact, while I could zero in on any single topic, I believe they walk in unison. Much like the Ideal Gas Law, you cannot change one of the parts (P, V, T, or n) without affecting all the others. Just as with an object in motion, no matter how complex the movement, it can be described instantaneously by a simple  X, Y and Z graph. A macro example of this is that the Earth appears flat over a short distance, or completely if you are a cultist, so we lose perspective of the whole picture.

    Similarly, most of us are so immersed in our jobs and lives, we only see “now,” “tomorrow,” and, maybe, “the day after tomorrow.” Yes, we may plan for months ahead for birthdays, vacations, etc., but, overall, we seldom look ahead decades in our professional disciplines. While “the future” seems far away, we are all chipping away at the present in unison, affecting the form that the future (next year?) will take. It is human nature to exist in our own silos and not notice what is happening next door until it knocks on, or knocks down, our front door.

    More and more, the “big Pharma boys” are slowly and finally responding to the economic pressures of doing everything themselves. When we observe the progression of outsourcing from, say, 1970 through 2000, it went from a few cases within national boundaries to much of what we do with many thousands of miles between sources and sponsor(s). Seldom was long-range planning involved as much as walking along the buffet table, testing ideas willy-nilly. Get our heparin from China, using 1950s tests for drug identity and purity? Sure, why not? What could possibly go wrong?

    So, at this point you might ask how all the topics work together. Simply put, we quote the basis of the nuclear arms treaty: “Trust, but verify.” Short of hiring and training tens of thousands of Agency inspectors and having at least one at every production and analytical facility in the world, there are some solutions between that and where we are today.

    First, the high potency APIs have some unique properties that need be kept in mind. The amounts of API, simply due to the higher potency (HP), can cause mixing and analysis difficulties. The dosage form itself is probably small, think birth control tablets, and can have on-line measurement difficulties. Methods (HPLC) might have extraction difficulties, e.g., for Assay, where 10-20 tablets are ground and aliquots are weighed into flasks. If Content Uniformity is performed, individual tablets are assayed. Due to the amount of HPAPI, smaller amounts of solvent in order to keep concentrations within analysis limits are used and, with poorly soluble APIs, this could lead to varying levels of extraction.

    On-line or near-line measurements, employing chemical imaging (CI), can help with homogeneity problems. Early imaging technologies were good, yet quite slow. As a reminder, CI produced a map of the material, mostly the surface, but can also see more of the internal structure, as well. The thousands of pixels, close to one or just a few particles within the tablet are displayed with their entire NIR spectrum. This 3-D data cube may be used to plot and quantify each component of a mixture: powder blend, tablet matrix, or capsule fill. The spectral plots produced are far better measures of amount and distribution than any traditional, wet method.

    Some new on-line NIR equipment is capable of qualifying—density, API-ID, dissolution prediction—and quantifying—% API, capsule fill—up to 100,000 tablets/capsules per line per hour. With this level of control, a dosage form with a small level of active may be made and sold with great confidence. In normal NIR—transmission or reflection—the spectrum is an average of all the ingredients, wherein a trace level of API might not register well. In a CI approach, aided with push-broom and spatially-resolved spectra, thousands of smaller spectra are generated, where the API is a major component in several pixels, allowing an accurate determination, rapidly.

    Many HP actives are also poorly soluble. This means the material needs to be in an amorphous form. The traditional batch process methodology for producing tablets can vary by quite a bit. Depending on the physical parameters, even in a PAT regulated program, varying amounts of blending and granulation, as well and varying levels depending on batch size can place varying stress—mechanical, heating—on the API. This warming can potentially transform the API into an even less soluble form, affecting in vivo therapeutic action.

    When you remove the variabilities in a production line, you can more easily control the physical conditions experienced by the HPAPI. For example, in a continuous manufacturing suite, all the lots, no matter how many doses manufactured. That is, at any point of the production cycle—weighing, blending, granulating—the amount of material residing at any point is constant and the same for all batches, large or small. With monitors at every point of the process, the integrity of the API can be evaluated. As with the CI above, monitoring the bulk material mitigates smaller percentages of API, allowing continuous analysis at all points.

    Now for the interesting part: tying all the points together. With massive numbers of contract organizations “hauling the water” for the large, but shrinking, Pharma companies, the supply chain refers to finished products and clinical supplies/tests, as well as “merely” API synthesis and raw material purchasing. Starting with contract labs/manufacturing/clinical groups (apropos to this magazine, no?), there seems to be a log-jam here. As large companies begin to universally embrace PAT, QbD, and CM, AND they also wish to use outsourcing more often, they are at a crossroad. They cannot produce more and more products via CM while the CMOs do not have or cannot afford the hardware, software and skillsets for CM.

    Pfizer has a program where it makes “pre-fab” CM suites, loaded on trailers, delivered to its remote sites, validated, and run as if they were at the location where the product was developed. Clearly, the validation process for a suite that was already validated and merely moved is less arduous than constructing one and validating in place. This concept may clearly be expanded to CMOs and clinical trial sites.

    In fact, using smaller, more easily modified processes for clinical work makes sense. If there is any question about varying dosage forms to give different blood levels and extended release performance, then smaller, more agile equipment makes perfect sense. Small batches with varying physical characteristics could be made in rapid order, without tearing down a process line, cleaning, and performing a cleaning validation. In addition, no matter how small a clinical batch, it can represent a “commercial-sized” batch as specified by the FDA for design-of-experiment studies, since a commercial sized batch is simply the CM suite run longer. Thus, the process parameters for a 10,000-tablet batch are identical with a 10,000,000-tablet batch.

    As for supply chain problems, this “out-reach” CM program can aid with all of them, as explained by the following:
    1. The overall product quality of “Product XYZ” will be the same, whether produced in Michigan or Manilla, since the same equipment, run under the same SOPs, using the same software controls will be producing the product.
    2. The inevitable differences in excipients, used at remote locations, may be addressed easily. Since it is not commercially viable for excipients to be shipped from the U.S. to other countries, it is a better idea to use RM testing SOPs, developed for the parent company. These would include NIRS and Raman for qualification for the contents all containers at the warehouse step. This helps keep records for moisture, particle size, etc. for batch records where they are used.
    3. The act of qualifying all incoming raw materials de facto also qualifies the suppliers of raw materials. Since there have been problems with relying on certificates of analysis from overseas suppliers, especially in developing countries, data generated by actual container-wise testing of incoming raw materials can help identify which suppliers are conforming to the date on CoA’s. This might lead to avoiding one or more suppliers.
    Now, if you put all these topics together (HPAPIs, global outsourcing, and clinical trials), you can see that “homogenizing” the manner of production—CM, NIR and Raman monitoring, 100% raw materials qualified, etc.—will go a long way to obviating constant inspections, rejected lots and recalled lots, and 483’s, and assure customers and Agencies around the world that the quality and availability of the products will be constant and satisfactory.

    As Henry Ford and all airlines found out, if you standardize parts, you save money and time, which equals money.


    Emil W. Ciurczak
    DoraMaxx Consulting

    Emil W. Ciurczak has worked in the pharmaceutical industry since 1970 for companies that include Ciba-Geigy, Sandoz, Berlex, Merck, and Purdue Pharma, where he specialized in performing method development on most types of analytical equipment. In 1983, he introduced NIR spectroscopy to pharmaceutical applications, and is generally credited as one of the first to use process analytical technologies (PAT) in drug manufacturing and development.
    Related Searches
    • blending
    • Capsules
    • api synthesis
    • quality
    Suggested For You
    Piramal Invests $32M to Expand Michigan Facility Piramal Invests $32M to Expand Michigan Facility
    Emphasizing Sustainability in Contract Manufacturing Emphasizing Sustainability in Contract Manufacturing
    Sterling Pharma Solutions Expands US Operations Sterling Pharma Solutions Expands US Operations
    Vetio Animal Health Vetio Animal Health
    Pfizer Signs $425m Flu Vaccine Deal with BioNTech Pfizer Signs $425m Flu Vaccine Deal with BioNTech
    Antares Enters Development Agreement With Pfizer Antares Enters Development Agreement With Pfizer
    Pfizer to Build Sterile Injectable Facility in MI Pfizer to Build Sterile Injectable Facility in MI
    Leap, Merck KGaA, Pfizer Partner for Cancer Leap, Merck KGaA, Pfizer Partner for Cancer
    01	Pfizer, Inc. 01 Pfizer, Inc.
    The Times, They Are a-Changin’ The Times, They Are a-Changin’
    Technological Arms Race Could Improve Bio Process Mfg. Efficiency Technological Arms Race Could Improve Bio Process Mfg. Efficiency
    Newsmakers: Flash Therapeutics Newsmakers: Flash Therapeutics
    The Final Frontier The Final Frontier
    BioMarin Receives Pfizer Milestone Payments BioMarin Receives Pfizer Milestone Payments
    Vectalys, Flashcell Merge to Form New Gene Therapy Company Vectalys, Flashcell Merge to Form New Gene Therapy Company

    Related Columns

    • Biologics, Proteins, Vaccines | Regulatory Affairs
      What Will Change at FDA for 2021?

      What Will Change at FDA for 2021?

      (R)evolution of the industry’s data, catalyzed by changes at FDA and what’s the likely impact to the pharmaceutical industry?
      Ben Locwin, Contributing Editor, International COVID-19 Advisor, Healthcare Futurist 04.01.21

    • Information Technology
      Life Sciences Strive for Greater Agility

      Life Sciences Strive for Greater Agility

      Embracing real-time drug safety monitoring during and post COVID will continue to propel the industry forward.
      Ronan Brown and Joe Rymsza, IQVIA 03.01.21

    • Biologics, Proteins, Vaccines
      Vaccines and Return-To-Normalcy

      Vaccines and Return-To-Normalcy

      Planning for a future in which COVID-19 won’t simply ‘disappear.’
      Ben Locwin, Contributing Editor 03.01.21


    • Chemistry | Laboratory Testing
      Back to the Future

      Back to the Future

      All that’s Old is New Again.
      Emil W. Ciurczak, DoraMaxx Consulting 03.01.21

    • Biologics, Proteins, Vaccines
      Vaccines 2021

      Vaccines 2021

      Looking at the behavioral economics of vaccinations.
      Ben Locwin, Contributing Editor 01.27.21

    • A Potential “Marriage”

      A Potential “Marriage”

      Initiator companies and generics/CMOs working together.
      Emil W. Ciurczak, DoraMaxx Consulting 11.17.20


    • When Politics and Science Collide

      When Politics and Science Collide

      COVID-19 illustrates why science should always be a principal informer of politics to make better and smarter decisions.
      Ben Locwin, Contributing Editor 11.17.20

    • The Pandemic’s Become an Insurmountable Opportunity

      The Pandemic’s Become an Insurmountable Opportunity

      Every Cloud has a Silver Lining(?)
      Emil W. Ciurczak, Contributing Editor 10.14.20

    • Biologics, Proteins, Vaccines
      It Takes a Vaccine… To End The Pandemic [У нас есть хорошая вакцина]

      It Takes a Vaccine… To End The Pandemic [У нас есть хорошая вакцина]

      Race for the vaccines is heating up.
      Ben Locwin, Contributing Editor 09.09.20


    • cGMP Manufacture
      Keys to Biotech Success

      Keys to Biotech Success

      Four steps emerging biotech companies can take to achieve success
      Thierry Cournez, Head of End-to-End Solutions, MilliporeSigma 06.04.20

    • Analytical Services
      What Happens When the All-Clear Signal is Given?

      What Happens When the All-Clear Signal is Given?

      Maybe 3M had some good ideas?
      Emil W. Ciurczak, DoraMaxx Consulting 06.04.20

    • Almost Like the Olympics:

      Almost Like the Olympics:

      “Smaller, Faster, Smarter”
      Emil W. Ciurczak, DoraMaxx Consulting 05.05.20


    • Rapid Delivery of Medical Countermeasures Amid Pandemic

      Rapid Delivery of Medical Countermeasures Amid Pandemic

      Robert Erwin of iBio discusses the company’s COVID-19 vaccine development efforts and FastPharming manufacturing platform for the rapid delivery of vaccines
      Kristin Brooks, Managing Editor, Contract Pharma 05.05.20

    • The Supply Chain House of Cards

      The Supply Chain House of Cards

      The COVID-19 pandemic exposes pressures on extended global supply chains
      Emil W. Ciurczak, DoraMaxx Consulting 04.01.20

    • Analytical Services | Laboratory Testing
      The Supply Chain, as Developed by IKEA (some assembly required)

      The Supply Chain, as Developed by IKEA (some assembly required)

      Pick One from Column A, Two from Column B, etc.
      Emil W. Ciurczak, DoraMaxx Consulting 03.04.20

    Trending
    • Astellas, Affinivax In Global MAPS Vax Pact
    • Ascendia Pharmaceuticals Poised For Expansion
    • Sanofi To Build New $700M Flu Vaccine Facility In Canada
    • Catalent Biologics Completes Madison Expansion
    • ANI Acquires Branded Products Portfolio From Sandoz
    Breaking News
    • Microbiologics Expands Virology Services
    • ATMPS, Ori Biotech Integrate Digital Platform for Cell & Gene Therapies
    • Executive Moves: Novavax
    • Albumedix Completes Commercial-Scale Mfg. Facility Expansion
    • Catalent Biologics Completes Madison Expansion
    View Breaking News >
    CURRENT ISSUE

    April 2021

    • Small Innovators & Niche CROs
    • Focus on Science
    • Rapid and Data Rich Chromatographic Method Development
    • Preparing Your Post Pandemic Talent Strategy
    • How Modern Near-Infrared Came to Be
    • Securing Your API Supply Chain: Three Keys to Success
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Four-Week Fish Oil Regimen Showed Significant Muscular Damage Protection in Recent Study
    Review Covers Role of Vitamin K2 in the ‘Calcium Paradox’
    KD Pharma Acquires Rohner AG Manufacturing Assets
    Coatings World

    Latest Breaking News From Coatings World

    Jebsen & Jessen, Innospec Sign Distribution Agreement
    Shepherd Color Unveils Bismuth Vanadate Yellow Pigment
    HMG Paints Reports Positive Feedback on Contract Matt Emulsion
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    BioSig Launches Software Update for PURE EP Electrophysiology Platform
    Katena Acquires Ophthalmic Surgical Instrument Maker ASICO
    Vicarious Surgical Appoints CFO and Chief Legal Officer
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Microbiologics Expands Virology Services
    ATMPS, Ori Biotech Integrate Digital Platform for Cell & Gene Therapies
    Executive Moves: Novavax
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Cosmoprof Worldwide Bologna Postpones 2021 Show
    Native Launches Broad Spectrum SPF 30 Mineral Sunscreens
    Revieve Launches Skin Coach
    Happi

    Latest Breaking News From Happi

    BASF Increases Price of Kaolin
    Kao Launches Online Beauty Store in Europe
    Neutrogena Takes Action on Skin Health Disparities
    Ink World

    Latest Breaking News From Ink World

    Kumon North America Adds Speedmaster XL 106 from Heidelberg
    SE-DA Invests in Kornit Presto S
    Acrylic Resins Market Worth $21.9 Billion by 2025: MarketsandMarkets
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Maxcess updates user interface for Fife guiding Sensor
    Bobst announces virtual packaging industry event
    Edale appoints agent in Poland
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    PFNonwovens Adding New Capabilities in Znojmo
    Russ Torres Named Group President of Kimberly-Clark North America
    Aries Face Masks Meet ASTM Standards
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Biogennix Rolls Out Agilon Strip Bone Graft
    Global Bone Tumor Ablation Devices Market to Top $111 Million by 2027
    GreenBone Ortho Closes 10 Million Euros Series B Funding Round
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Virtual ASMC 2021 Spotlights Advanced Semiconductor Manufacturing Excellence
    European Commission's Innovation Radar Acknowledges 3 ARMOR Innovations
    SUPERSMART Wins 'Best Publicly Funded Project Demonstrator' in 2021 OE-A Competition

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login